{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T22:25:42Z","timestamp":1789424742792,"version":"build-2803163510"},"reference-count":30,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T00:00:00Z","timestamp":1721606400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"CureSMA"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJNS"],"abstract":"<jats:p>Spinal muscular atrophy (SMA) is an autosomal recessive condition characterized by alpha motor neuron degeneration in the spinal cord anterior horn. Clinical symptoms manifest in the first weeks to months of life in the most severe cases, resulting in progressive symmetrical weakness and atrophy of the proximal voluntary muscles. Approximately 95% of SMA patients present with homozygous deletion of the SMN1 gene. With multiple available therapies preventing symptom development and slowing disease progression, newborn screening for SMA is essential to identify at-risk individuals. From 2018 to 2023, a total of 239,844 infants were screened. 13 positive screens were confirmed to have SMA. An additional case was determined to be a false positive. We are not aware of any false-negative cases. All patients were seen promptly, with diagnosis confirmed within 1 week of the initial clinical visit. Patients were treated with nusinersen or onasemnogene abeparvovec. Treated patients with two copies of SMN2 are meeting important developmental milestones inconsistent with the natural history of type 1 SMA. Patients with 3\u20134 copies of SMN2 follow normal developmental timelines. Newborn screening is an effective tool for the early identification and treatment of patients with SMA. Presymptomatic treatment dramatically shifts the natural history of SMA, with most patients meeting appropriate developmental milestones. Patients with two copies of SMN2 identified through newborn screening constitute a neurogenetic emergency. Due to the complexities of follow-up, a multidisciplinary team, including close communication with the newborn screening program, is required to facilitate timely diagnosis and treatment.<\/jats:p>","DOI":"10.3390\/ijns10030054","type":"journal-article","created":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T17:36:04Z","timestamp":1721669764000},"page":"54","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["A Five-Year Review of Newborn Screening for Spinal Muscular Atrophy in the State of Utah: Lessons Learned"],"prefix":"10.3390","volume":"10","author":[{"given":"Kristen N.","family":"Wong","sequence":"first","affiliation":[{"name":"Department of Pediatrics, University of Utah, Salt Lake City, UT 84113, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"McIntyre","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Utah, Salt Lake City, UT 84113, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabina","family":"Cook","sequence":"additional","affiliation":[{"name":"Utah Newborn Screening Program, Salt Lake City, UT 84129, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Hart","sequence":"additional","affiliation":[{"name":"Utah Newborn Screening Program, Salt Lake City, UT 84129, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amelia","family":"Wilson","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Utah, Salt Lake City, UT 84113, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Moldt","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Utah, Salt Lake City, UT 84113, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Rohrwasser","sequence":"additional","affiliation":[{"name":"Utah Newborn Screening Program, Salt Lake City, UT 84129, USA"},{"name":"Myotonic Dystrophy Foundation, Oakland, CA 94612, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8452-7189","authenticated-orcid":false,"given":"Russell J.","family":"Butterfield","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Utah, Salt Lake City, UT 84113, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,7,22]]},"reference":[{"key":"ref_1","unstructured":"Adam, M.P., Feldman, J., Mirzaa, G.M., Pagon, R.A., Wallace, S.E., Bean, L.J.H., Gripp, K.W., and Amemiya, A. (2023, February 28). Spinal Muscular Atrophy. [2000 February 24 Updated 2020 December 3], GeneReviews\u00ae [Internet], Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK1352\/."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Nicolau, S., Waldrop, M.A., Connolly, A.M., and Mendell, J.R. (2021). Spinal Muscular Atrophy. Seminars in Pediatric Neurology, W.B. Saunders.","DOI":"10.1016\/j.spen.2021.100878"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1212\/CON.0000000000000918","article-title":"Spinal Muscular Atrophy","volume":"26","author":"Nance","year":"2020","journal-title":"Continuum Lifelong Learn. Neurol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.nmd.2018.01.003","article-title":"Correlation between SMA type and SMN2 copy number revisited: An analysis of 625 unrelated Spanish patients and a compilation of 2834 reported cases","volume":"28","author":"Calucho","year":"2018","journal-title":"Neuromuscul. Disord."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13023-017-0671-8","article-title":"Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy\u2014A literature review","volume":"12","author":"Verhaart","year":"2017","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1038\/s41591-022-01867-3","article-title":"Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: The Phase III SPR1NT trial","volume":"28","author":"Strauss","year":"2022","journal-title":"Nat. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1038\/s41591-022-01866-4","article-title":"Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: The Phase III SPR1NT trial","volume":"28","author":"Strauss","year":"2022","journal-title":"Nat. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.nmd.2019.09.007","article-title":"Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study","volume":"29","author":"Darryl","year":"2019","journal-title":"Neuromuscul. Disord."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/mus.27853","article-title":"Continued benefit of nusinersen initiated in the presymptomatic stage of spinal muscular atrophy: 5-year update of the NURTURE study","volume":"68","author":"Crawford","year":"2023","journal-title":"Muscle Nerve"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","article-title":"Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy","volume":"377","author":"Mendell","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1212\/WNL.0000000000002445","article-title":"Results from a phase 1 study of nusinersen (ISIS-SMN Rx) in children with spinal muscular atrophy","volume":"86","author":"Chiriboga","year":"2016","journal-title":"Neurology"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Rousseau, F., Gigure, Y., Berthier, M.-T., Gurette, D., Girard, J.-G., and Dry, M. (2012). Newborn Screening by Tandem Mass Spectrometry: Impacts, Implications and Perspectives. Tandem Mass Spectrometry\u2014Applications and Principles, InTech.","DOI":"10.5772\/33118"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1S","DOI":"10.1097\/01.gim.0000223891.82390.ad","article-title":"Newborn screening: Toward a uniform screening panel and system","volume":"8","author":"Watson","year":"2006","journal-title":"Genet. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"E1527","DOI":"10.1212\/WNL.0000000000200986","article-title":"Newborn Screening for Spinal Muscular Atrophy in New York State: Clinical Outcomes From the First 3 Years","volume":"99","author":"Lee","year":"2022","journal-title":"Neurology"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3233\/JND-180304","article-title":"Treatment Algorithm for Infants Diagnosed with Spinal Muscular Atrophy through Newborn Screening","volume":"5","author":"Glascock","year":"2018","journal-title":"J. Neuromuscul. Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3233\/JND-190468","article-title":"Revised Recommendations for the Treatment of Infants Diagnosed with Spinal Muscular Atrophy Via Newborn Screening Who Have 4 Copies of SMN2","volume":"7","author":"Glascock","year":"2020","journal-title":"J. Neuromuscul. Dis."},{"key":"ref_17","unstructured":"CureSMA (2024, January 28). 100% of States Now Screening Newborns for SMA. Available online: https:\/\/www.curesma.org\/100-of-states-now-screening-newborns-for-sma\/."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.nmd.2009.11.014","article-title":"The Children\u2019s Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND): Test development and reliability","volume":"20","author":"Glanzman","year":"2010","journal-title":"Neuromuscul. Disord."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1097\/PEP.0b013e3182351f04","article-title":"Validation of the Children\u2019s Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND)","volume":"23","author":"Glanzman","year":"2011","journal-title":"Pediatr. Phys. Ther."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Bayley, N. (2005). Bayley Scales of Infant and Toddler Development, APA PsycTests. [3rd ed.]. (Bayley\u2013III\u00ae).","DOI":"10.1037\/t14978-000"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/ejhg.2011.134","article-title":"Pan-ethnic carrier screening and prenatal diagnosis for spinal muscular atrophy: Clinical laboratory analysis of >72,400 specimens","volume":"20","author":"Sugarman","year":"2012","journal-title":"Eur. J. Hum. Genet."},{"key":"ref_22","unstructured":"Romero, S., Biggio, J.R., Saller, D.N., and Giardine, R. (2023, February 23). Committee Opinion Number 432. Available online: https:\/\/www.acog.org\/clinical\/clinical-guidance\/committee-opinion\/articles\/2017\/03\/carrier-screening-for-genetic-conditions."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13023-021-01783-8","article-title":"Newborn screening for spinal muscular atrophy in Germany: Clinical results after 2 years","volume":"16","author":"Vill","year":"2021","journal-title":"Orphanet. J. Rare Dis."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"389","DOI":"10.3233\/JND-220789","article-title":"Spinal Muscular Atrophy\u2014Is Newborn Screening Too Late for Children with Two SMN2 Copies?","volume":"9","author":"Schwartz","year":"2022","journal-title":"J. Neuromuscul. Dis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1093\/brain\/awac125","article-title":"Pre-symptomatic spinal muscular atrophy: A proposed nosology","volume":"145","author":"Finkel","year":"2022","journal-title":"Brain"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1172\/JCI121658","article-title":"Two breakthrough gene-targeted treatments for spinal muscular atrophy: Challenges remain","volume":"128","author":"Sumner","year":"2018","journal-title":"J. Clin. Investig."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"19006","DOI":"10.3390\/s150819006","article-title":"Daily quantity of infant leg movement: Wearable sensor algorithm and relationship to walking onset","volume":"15","author":"Smith","year":"2015","journal-title":"Sensors"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1123\/jmld.2016-0056","article-title":"Differences in spontaneous leg movement patterns between infants with typical development and infants at risk for developmental delay: Cross-sectional observation prior to sitting onset","volume":"6","author":"Deng","year":"2018","journal-title":"J. Mot. Learn. Dev."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1109\/JTEHM.2019.2893223","article-title":"Identification of developmental delay in infants using wearable sensors: Full-day leg movement statistical feature analysis","volume":"7","author":"Abrishami","year":"2019","journal-title":"IEEE J. Transl. Eng. Health Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1097\/PEP.0000000000001053","article-title":"Daily Quantity and Kinematic Characteristics of Leg Movement in a Child with SMA (2 Copies SMN2)","volume":"35","author":"McIntyre","year":"2023","journal-title":"Pediatr. Phys. Ther."}],"container-title":["International Journal of Neonatal Screening"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2409-515X\/10\/3\/54\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:21:12Z","timestamp":1760109672000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2409-515X\/10\/3\/54"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,22]]},"references-count":30,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,9]]}},"alternative-id":["ijns10030054"],"URL":"https:\/\/doi.org\/10.3390\/ijns10030054","relation":{},"ISSN":["2409-515X"],"issn-type":[{"value":"2409-515X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,22]]}}}